What is Medtronic PLC's stock symbol?
Medtronic PLC trades on the New York Stock Exchange (NYSE) under the ticker symbol "MDT."
How often does Medtronic PLC pay dividends? What is the dividend yield for Medtronic PLC?
Medtronic PLC announced a quarterly dividend on Friday, December 9th. Stockholders of record on Friday, December 23rd will be paid a dividend of $0.43 per share on Friday, January 13th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 2.12%. The ex-dividend date of this dividend is Wednesday, December 21st.
Where is Medtronic PLC's stock going? Where will Medtronic PLC's stock price be in 2017?
25 brokerages have issued 1 year target prices for Medtronic PLC's stock. Their forecasts range from $77.00 to $102.00. On average, they anticipate Medtronic PLC's stock price to reach $87.71 in the next year.
When will Medtronic PLC announce their earnings?
Medtronic PLC is scheduled to release their next quarterly earnings announcement on Thursday, May, 25th 2017.
What are analysts saying about Medtronic PLC stock?
Here are some recent quotes from research analysts about Medtronic PLC stock:
According to Zacks Investment Research, "Medtronic posted better-than-expected fiscal third-quarter results with both earnings and revenues ahead of the Zacks Consensus Estimate. All major business groups contributed to solid top-line growth at CER indicating sustainability across groups and regions. However, escalating costs and expenses weighed on margins. Also, unfavorable foreign exchange continues to remain a drag. This has been reflected in the company’s share price trend too. In the past 6 months, Medtronic consistently traded below the Zacks categorized Medical Product industry and a dull fiscal guidance fails to indicate any chances of respite soon. On a positive note, we are encouraged by the solid growth trend in the U.S. as well as the healthy global acceptance of its therapies. Apart from product innovation, the company is currently focusing on geographical diversification of its businesses." (2/23/2017)
- Wedbush analysts commented, "Medtronic's broad product portfolio allows the company to navigate through temporary disruptions it might encounter in any given business unit, and today's FY3Q17 earnings results showcased management's ability to leverage its size and recover more quickly than we had expected from its disappointing FY2Q17 performance reported in November. With MDT's share price having mostly recovered from the post FY2Q17 selloff, we believe current valuation levels adequately reflect MDT's risk/reward profile and prefer to wait on the sidelines for a better entry point. ' FY3Q17 revenue of $7,283 million (+6% yr/yr, ex-FX) beat consensus revenue estimate of $7,220 million. Revenue from all four segments exceeded consensus, with the biggest contribution from Minimally Invasive Therapies Group (MTIG) and Diabetes' Our $85 PT is based on applying a 16x P/E multiple on our MDT forward EPS estimate, 12 months hence." (2/22/2017)
- Needham & Company LLC analysts commented, "F3Q17 revenue and EPS beat consensus and MDT maintained its FY17 guidance. Organic revenue growth increased to 4.1% CC vs. 2.2% CC in F1Q17 with new products adding ~390 bps, emerging markets adding ~150 bps and services & solutions adding ~20 bps (yielding reported revenue growth of 5.6% CC). Operating margin was just below consensus and up 40 bps Y/Y (or 130 bps Y/ Y CC). Importantly, management reiterated its longer-term target of mid-single digit revenue growth and double-digit EPS growth. MDT noted it expects to offset the impact of competitors' new product launches (e.g. MRI devices) with its own new product launches. MDT shares remain at a discount to peers and we reiterate our Buy rating." (2/21/2017)
- Evercore ISI analysts commented, "MDT started 2017 with a solid execution, highlighted by all around revenue beat and operating margins that were generally in line with ST (came in above us). The importance of this Q cannot be underestimated in our mind, as sentiment had turned negative (post a disappointing 1H) and the stock multiple (3-6x discount to peer group) was see-sawing precariously at ~15-16x P/E. While the bar had been lowered, MDT needed to deliver to flawless Q to instill investor confidence and start the path towards multiple correction (vs. group). The company began its first step, highlighted by a solid revenue beat, driven by high single digit growth in CR&HF. This is a key segment, and the ~8% growth should provide comfort against the bear thesis of competitive share losses / replacement cycle headwinds. We were also encouraged to see ~30% growth in TAVR, and a full rollout of the 34mm valve (launched only in 50% of centers) plus Intermediate Risk approval in early 2018 bodes well. Other key drivers in 2018 include the full commercial launch of 670G in Diabetes, Resolute Onyx launch, continued growth in AF, Link, DCBs, and the continued turnaround in Spine provides incremental confidence in MDT being able to sustain ~4% organic topline in the medium term. The second leg of value creation will rest on margin expansion, with the ST still skeptical of the company's ability to show margin expansion on a reported basis (including the impact of Fx hedges). We believe that the margin expansion thesis will play out in 2018, and will play a huge role in MDT's ability to close its P/E gap vs. peer group average. We expect this combination of a potential multiple reflation trade along with upside from capital deployment (incremental ~$3 Bn could potentially be accessible in near term post IRS settlement) to drive value for investors over the next 12 months." (2/21/2017)
- Jefferies Group LLC analysts commented, "Heading into results next week, we are updating our model for FX and revisiting some of the recent themes at MDT. Among the issues to watch: FX gains will again confound the outlook, with FY18 consensus numbers likely too high; the pace of underling margin gains against the targets laid out last year; and how increasing competition in CRM, Neuro, TAVR, etc can be offset by Spine, Diabetes, Robotics, EM, etc to keep growth in the mid-single digits." (2/17/2017)
Who owns Medtronic PLC stock?
Medtronic PLC's stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (4.66%), FMR LLC (4.29%), Franklin Resources Inc. (2.71%), Artisan Partners Limited Partnership (1.74%), Barrow Hanley Mewhinney & Strauss LLC (1.50%) and Dimensional Fund Advisors LP (0.58%). Company insiders that own Medtronic PLC stock include Bryan C Hanson, Carol A Surface, Gary Lee Ellis, Geoffrey Martha, James T Lenehan, Kendall J Powell, Omar Ishrak, Richard Kuntz, Robert C Pozen and Shirley A Jackson.
Who sold Medtronic PLC stock? Who is selling Medtronic PLC stock?
Medtronic PLC's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Artisan Partners Limited Partnership, I.G. Investment Management LTD., Federated Investors Inc. PA, Institutional Capital LLC, Marshall Wace LLP, Bessemer Group Inc. and Comgest Global Investors S.A.S.. Company insiders that have sold Medtronic PLC stock in the last year include Bryan C Hanson, Carol A Surface, Gary Lee Ellis, Geoffrey Martha, Kendall J Powell, Omar Ishrak, Richard Kuntz and Shirley A Jackson.
Who bought Medtronic PLC stock? Who is buying Medtronic PLC stock?
Medtronic PLC's stock was purchased by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Russell Investments Group Ltd., DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main, Janus Capital Management LLC, Barrow Hanley Mewhinney & Strauss LLC, State Street Corp, Equity Investment Corp Acquisition Inc and Thrivent Financial for Lutherans. Company insiders that have bought Medtronic PLC stock in the last two years include James T Lenehan and Robert C Pozen.
How do I buy Medtronic PLC stock?
Shares of Medtronic PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Medtronic PLC stock cost?
One share of Medtronic PLC stock can currently be purchased for approximately $81.03.